Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kayode Ogungbenro

Showing results (31-40 of 95) with videos related to

Pageof 10
Sort By:
Clinical Pharmacology and Therapeutics|December 7, 2020
Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case StudyJennifer Lang, Ludwig Vincent, Marylore Chenel, et al.
The Journal of Pharmacy and Pharmacology|May 25, 2019
An evaluation of cetuximab dosing strategies using pharmacokinetics and cost analysisKayode Ogungbenro, Alkesh Patel, Mark Saunders, et al.
Computer Methods and Programs in Biomedicine|February 13, 2007
A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic modelsIvelina Gueorguieva, Kayode Ogungbenro, Gordon Graham, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 14, 2021
Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactionsJennifer Lang, Ludwig Vincent, Marylore Chenel, et al.
Expert Opinion on Drug Metabolism & Toxicology|April 28, 2011
Translational pharmacokinetics: challenges of an emerging approach to drug development in strokeAndrew D Greenhalgh, Kayode Ogungbenro, Nancy J Rothwell, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 17, 2023
A "middle-out approach" for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) modelsEstelle Yau, Michael Gertz, Kayode Ogungbenro, et al.
British Journal of Clinical Pharmacology|July 17, 2021
Evaluation of area under the concentration curve adjusted by the terminal-phase as a metric to reduce the impact of variability in bioequivalence testingAdam J Lucas, Kayode Ogungbenro, Shuying Yang, et al.
The Journal of Pharmacy and Pharmacology|June 28, 2017
Choosing an optimal input for an intravenous glucose tolerance test to aid parameter identificationEmma C Martin, James W T Yates, Kayode Ogungbenro, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 8, 2023
Investigation of simplified physiologically-based pharmacokinetic models in rat and humanEstelle Yau, Andrés Olivares-Morales, Kayode Ogungbenro, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 19, 2015
Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonistKayode Ogungbenro, Sharon Hulme, Nancy Rothwell, et al.
Pageof 10

Showing results (31-40 of 95) with videos related to

Sort By:
Pageof 10
Clinical Pharmacology and Therapeutics|December 7, 2020
Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case StudyJennifer Lang, Ludwig Vincent, Marylore Chenel, et al.
The Journal of Pharmacy and Pharmacology|May 25, 2019
An evaluation of cetuximab dosing strategies using pharmacokinetics and cost analysisKayode Ogungbenro, Alkesh Patel, Mark Saunders, et al.
Computer Methods and Programs in Biomedicine|February 13, 2007
A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic modelsIvelina Gueorguieva, Kayode Ogungbenro, Gordon Graham, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 14, 2021
Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactionsJennifer Lang, Ludwig Vincent, Marylore Chenel, et al.
Expert Opinion on Drug Metabolism & Toxicology|April 28, 2011
Translational pharmacokinetics: challenges of an emerging approach to drug development in strokeAndrew D Greenhalgh, Kayode Ogungbenro, Nancy J Rothwell, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 17, 2023
A "middle-out approach" for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) modelsEstelle Yau, Michael Gertz, Kayode Ogungbenro, et al.
British Journal of Clinical Pharmacology|July 17, 2021
Evaluation of area under the concentration curve adjusted by the terminal-phase as a metric to reduce the impact of variability in bioequivalence testingAdam J Lucas, Kayode Ogungbenro, Shuying Yang, et al.
The Journal of Pharmacy and Pharmacology|June 28, 2017
Choosing an optimal input for an intravenous glucose tolerance test to aid parameter identificationEmma C Martin, James W T Yates, Kayode Ogungbenro, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 8, 2023
Investigation of simplified physiologically-based pharmacokinetic models in rat and humanEstelle Yau, Andrés Olivares-Morales, Kayode Ogungbenro, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 19, 2015
Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonistKayode Ogungbenro, Sharon Hulme, Nancy Rothwell, et al.
Pageof 10